Evidence map›Paper›PMID 32839457›Full record

ArticleNPJ systems biology and applications2020

Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.

Niclas Björn, Tejaswi Venkata Satya Badam, Rapolas Spalinskas, Eva Brandén, Hirsh Koyi, Rolf Lewensohn, Luigi De Petris, Zelmina Lubovac-Pilav, Pelin Sahlén, Joakim Lundeberg and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ systems biology and applications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Niclas Björn *Clinical Pharmacology, Division of Drug Research, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. niclas.bjorn@liu.se.ORCID http://orcid.org/0000-0001-6806-4527
Tejaswi Venkata Satya Badam *Bioinformatics, Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0002-6719-4861
Rapolas SpalinskasScience for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, Department of Gene Technology, KTH Royal Institute of Technology, Solna, Sweden.ORCID http://orcid.org/0000-0002-1648-6426
Eva BrandénDepartment of Respiratory Medicine, Gävle Hospital, Gävle, Sweden.
Hirsh KoyiDepartment of Respiratory Medicine, Gävle Hospital, Gävle, Sweden.ORCID http://orcid.org/0000-0001-5797-7873
Rolf LewensohnThoracic Oncology Unit, Tema Cancer, Karolinska University Hospital, and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Luigi De PetrisThoracic Oncology Unit, Tema Cancer, Karolinska University Hospital, and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Zelmina Lubovac-PilavSchool of Bioscience, Systems Biology Research Centre, University of Skövde, Skövde, Sweden.ORCID http://orcid.org/0000-0001-6427-0315
Pelin SahlénScience for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, Department of Gene Technology, KTH Royal Institute of Technology, Solna, Sweden.
Joakim LundebergScience for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, Department of Gene Technology, KTH Royal Institute of Technology, Solna, Sweden.ORCID http://orcid.org/0000-0003-4313-1601
Mika GustafssonBioinformatics, Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0002-0048-4063
Henrik GréenClinical Pharmacology, Division of Drug Research, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Linköping University · SEScience for Life Laboratory · SEKarolinska University Hospital · SEUppsala University · SEUniversity of Skövde · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine/carboplatin chemotherapy commonly induces myelosuppression, including neutropenia, leukopenia, and thrombocytopenia. Predicting patients at risk of these adverse drug reactions (ADRs) and adjusting treatments accordingly is a long-term goal of personalized medicine. This study used whole-genome sequencing (WGS) of blood samples from 96 gemcitabine/carboplatin-treated non-small cell lung cancer (NSCLC) patients and gene network modules for predicting myelosuppression. Association of genetic variants in PLINK found 4594, 5019, and 5066 autosomal SNVs/INDELs with p ≤ 1 × 10

Indexed as

Whole Genome SequencingBone MarrowCarboplatinCarcinoma, Non-Small-Cell LungDeoxycytidineGemcitabineGene Regulatory NetworksHumansLung NeoplasmsCarboplatinDeoxycytidineGemcitabine

Identifiers

PMID32839457
PMCPMC7445166
OpenAlexW3081311033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.